Navigation Links
NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
Date:10/25/2007

BEDMINSTER, N.J., Oct. 25 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its third quarter financial results and Nycomed's decision whether to proceed with ex-U.S. development and commercialization of GATTEX(TM) (teduglutide) on Thursday, November 1, 2007. NPS expects to receive notification from Nycomed at the end of this month regarding Nycomed's plans to partner with NPS on the development of GATTEX(TM) (teduglutide) outside North America. The announcement will be followed by a conference call and webcast at 5:00 p.m. EDT, featuring Dr. Anthony Coles, president and CEO, and other members of the NPS executive team.

To participate in the conference call, dial (866) 770-7051 and use passcode 53288322. International callers may dial (617) 213-8064, using the same passcode. In addition, live audio of the conference call will be simultaneously broadcast over the Internet and may be accessed on the company's web site (http://www.npsp.com).

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 16038876, until midnight EST, November 15, 2007. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available on the NPS website for the same period of time.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. Versatile Reporter Vectors for Monitoring Viral Transduction
8. In Vivo Signal Transduction Pathway Reporting Systems
9. Improved Vectors for PathDetect Trans-Reporting Systems
10. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
11. Cis-Reporting System Monitors Intracellular Calcium Mobilization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):